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quence of cardiac operations.1-4 The prevalence of peri-
operative myocardial infarction is reported between 5%
and 21%.5-10 The pathophysiology of postoperative
myocardial injury is complex and results from a combi-
nation of ischemia-reperfusion injury11,12 and the sys-
temic inflammatory response syndrome.13,14
Platelet activating factor (PAF), whose circulating
concentration increases by around 350% during car-
diopulmonary bypass (CPB),15 regulates both respons-
es, which depend on activation and adhesion of circu-
lating leukocytes to microvascular endothelium.16
PAF, a glycerol phospholipid synthesized by a variety
of cells, is a particularly potent bioactive mediator of
inflammation and produces cell damage by several
mechanisms.17 As a major stimulator of neutrophil
integrin expression, PAF controls neutrophil activa-
Specific biochemical markers demonstrate that somedegree of myocardial injury is an inevitable conse-
Objective: Platelet activating factor antagonists reduce ischemia-reperfusion
injury in experiments, but there is no supportive clinical evidence.
Methods: A single-center, double-blind, minimized, placebo-controlled, ran-
domized trial of low-dose (10 mg) or high-dose (100 mg) platelet activating
factor antagonist was conducted in 150 patients undergoing coronary artery
bypass grafting. Myocardial injury was determined by serial measurements
of the MB isoenzyme of creatine kinase and cardiac troponin T. The effects
of single or bilateral internal thoracic artery grafting and coronary
endarterectomy on myocardial injury were also assessed.
Results: The placebo and platelet activating factor antagonist groups were
similar with respect to preoperative, intraoperative, and postoperative fac-
tors. Four patients (2.7%) died before discharge, 3 from cardiac events.
Thirteen patients (9%) had biochemical evidence of myocardial infarction,
of whom 3 died. Stepwise multiple regression analysis demonstrated that
duration of cardiopulmonary bypass was the most important determinant of
elevations in creatine kinase MB isoenzyme and cardiac troponin T up to 6
hours after the operation and that the use of a platelet activating factor antag-
onist and the number of internal thoracic artery grafts did not influence
myocardial injury at any time. Endarterectomy was performed in 11 patients
(7%), of whom 6 (55%) had biochemically defined myocardial infarction
and of whom 1 died (9%). Endarterectomy was the most important determi-
nant of elevated levels of creatine kinase MB isoenzyme and cardiac tro-
ponin T 24 and 48 hours after the operation.
Conclusion: Platelet activating factor antagonists do not reduce perioperative
myocardial injury. Bilateral and single internal thoracic artery grafting
results in similar levels of myocardial injury, whereas endarterectomy is fre-
quently associated with biochemical evidence of myocardial injury. (J
Thorac Cardiovasc Surg 2000;120:651-9)
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tion, chemotaxis, and diapedesis and is responsible
for neutrophil-mediated tissue injury.17 At a local
level, PAF is a major endogenous mediator of neu-
trophil aggregation in ischemia-reperfusion injury,18
and several experimental models have reported the
efficacy of PAF antagonists in abolishing or reducing
its consequences.17-20 In addition to causing direct
myocardial injury, PAF has several adverse hemody-
namic consequences, including coronary vasospasm,
negative inotropy, and an increase in cardiac arrhyth-
mia.17-20 To date, however, there has been no report of
the ability of a PAF antagonist to reduce myocardial
injury in clinical practice.
The primary aim of this study was to examine the
potential of a PAF antagonist to reduce myocardial
injury in coronary artery bypass grafting. In a single-
center, double-blind, minimized, placebo-controlled,
randomized trial, the effects of low-dose (10 mg) or
high-dose (100 mg) PAF antagonist were assessed by
serial measurements of the MB isoenzyme of creatine
kinase (CK-MB) and cardiac troponin T (cTnT). My
colleagues and I1-4 have previously used these markers
to quantify myocardial injury and to assess interven-
tions in adults and children undergoing cardiac opera-
tions. A secondary aim was to examine the effects of
single or bilateral internal thoracic artery (ITA) grafting
and coronary endarterectomy on myocardial injury.
Methods
Patients. The 150 patients undergoing CPB in the current
study were enrolled in a randomized controlled trial of a PAF
antagonist (lexipafant) between February 1996 and March
1997. The Central Oxford Research Ethics Committee
approved the study, and written informed consent was
obtained from all patients.
The inclusion criteria for the study included patients under-
going first-time coronary artery bypass grafting for angio-
graphically demonstrated coronary stenoses. Exclusion crite-
ria included emergency surgery, significantly impaired
ventricular function (ejection fraction < 30%), or a previous
cerebrovascular accident.
Lexipafant (BB-882) is a PAF antagonist developed by
British Biotech Pharmaceuticals Ltd, Oxford, United
Kingdom. It is well tolerated with potent ex vivo PAF antag-
onism demonstrated at both blood (platelet aggregation) and
tissue level (intradermal weal and flare response). Lexipafant
was administered intravenously in a total dose of 10 mg (0.4-
mg bolus followed by 0.4 mg/h for 24 hours) or 100 mg (4-
mg bolus followed by 4 mg/h for 24 hours). A standard dose
of 100 mg in 24 hours provides steady state levels of drug
between 50 and 150 ng/mL. Pharmacokinetic extrapolations
predict that a level of 2 ng/mL is sufficient to block exoge-
nous effects of PAF such as platelet aggregation. The levels
needed for a therapeutic effect are uncertain but are expected
to be high to block endogenous PAF released in high concen-
tration in direct cell-to-cell interaction. In volunteers, steady
state blood levels in the range of 500 to 800 ng/mL have been
achieved without untoward effect.
Power calculations. A sample size of 50 patients per
group was sufficient to show, with at least 80% power, a sig-
nificant difference in mean changes from baseline in CK-MB
levels at 24 hours, assuming a population mean change from
baseline in an active group equal to 15% of the placebo mean
change (ie, an 85% reduction) and population standard devi-
ations (SDs) of changes in each group of 48 ng/mL. The esti-
mates of the placebo mean change and of the within-group
SD were based on blinded data from the combined placebo
and active groups in study D06/IVB/252.
Randomization. Treatment allocation was by a double-
blind process of minimization using the British Biotech min-
imization program. Minimization was used so that the 2
treatment groups would be balanced with respect to age (<40,
40-49, 59-59, 60-69, >70 years), sex, number of vessels
affected (left main stem, three vessels, one or two vessels),
previous percutaneous transluminal coronary angioplasty
(yes/no), surgeon (David P. Taggart or Ravi Pillai), aspirin
therapy (yes/no), and left ventricular function (normal/
impaired). When a patient was to be entered into the study,
the relevant details were faxed to British Biotech, and the
computer program determined the treatment group to which
the patient was to be allocated; the patient was assigned to the
next available subject number from the pre-determined ran-
domization schedule. Details of the allocation were stored in
the computer.
Anesthesia. All patients received the same anesthetic regi-
men. Premedication was achieved with morphine (10-15 mg)
and scopolamine (0.3-0.4 mg). Anesthesia was induced with
fentanyl (1 mg), pancuronium (8 mg), and etomidate (4-10 mg).
Anesthesia was maintained with a combination of oxygen,
nitrous oxide, and halothane before CPB and with propofol (6
mg/kg per hour) during CPB. Benzodiazepines were not used.
Surgery. The operations were performed by two consultant
surgeons using intermittent aortic crossclamping and fibrilla-
tion (135 patients) or by supervised surgeons in training using
antegrade cold crystalloid cardioplegia (1 L St Thomas’
Hospital solution) in 15 patients.
CPB. CPB was achieved with a pump flow rate of 2.4 L ·
m2 · min at normothermia with the temperature allowed to
drift to 34°C. Topical cooling was not used, and there was no
direct or indirect left ventricular venting. A Cobe CML mem-
brane oxygenator (Cobe Cardiovascular, Inc, Arvada, Calif)
and a roller pump producing nonpulsatile flow were used
without an arterial line filter. Alpha-stat control of acid-base
management was used and the mean arterial pressure was
maintained between 50 and 60 mm Hg with pharmacologic
manipulation if necessary.
Postoperative management. All patients were managed
by the same standardized cardiovascular, respiratory, and
renal protocols aimed at early extubation. Timing of extuba-
tion was managed by the nursing staff in alert, hemodynami-
cally stable patients capable of maintaining self-ventilation.
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Measurement of CK-MB and cTnT. Blood samples were
taken for analysis of cTnT and CK-MB pre-dose and at 1, 6,
24, and 48 hours after CPB. All cTnT assays used
heparinized plasma samples. CK-MB assays used plasma
samples treated with ethylenediaminetetraacetic acid in all
except 20 subjects, in whom heparinized plasma samples
were used. Assays of cTnT were done at the Analytical Unit,
St George’s Hospital Medical School, London, with the use
of the ES-300 Immunoassay analyzer, which carries out a 1-
step enzyme-linked immunosorbent assay using a mixture of
two anti-cTnT monoclonal antibodies. Boehringer Mann-
heim Ltd, East Sussex, produced the kit. The lower limit of
quantification was 0.02 µg/L. CK-MB was determined at The
Analytical Unit, St George’s Hospital Medical School, with
the use of a paramagnetic-particle, chemiluminescent
immunoassay on the Access immunoassay system. Sanofi
Diagnostics Pasteur Ltd, Surrey, produced reagents. The
lower limit of quantification was 0.3 µg/L.
Definition of perioperative myocardial infarction.
Perioperative myocardial infarction was defined as a rise in
both CK-MB and cTnT at 24 and/or 48 hours above the
respective values at 6 hours.
Statistical analysis.  Statistical analysis was undertaken
with the SPSS computer program (version 9.0, SPSS, Inc,
Chicago, Ill). Data are presented as mean (SD) or median
(interquartile range) as appropriate. Areas under the curve
were computed by means of the linear trapezoid rule and log
transformed to account for skewed distribution. Demographic
data among the 3 groups were combared by analysis of vari-
ance or the Kruskal-Wallis test as appropriate.
Minimization was employed during randomization to
ensure equal distribution of known factors such as age, sex,
number of vessels affected, previous angioplasty, surgeon,
aspirin therapy, and left ventricular function. Biochemical
markers of myocardial injury (dependent variable) in the 3
groups were analyzed by stepwise linear regression analysis;
randomization group, differing use of ITA grafts, duration of
CPB, presence or absence of endarterectomy, and method of
myocardial protection were used as independent variables.
Results
Patient characteristics and intraoperative and postop-
erative data are summarized in Table I. The placebo and
low- and high-dose PAF antagonist groups were simi-
lar with respect to age, sex, urgency of operation, pre-
operative aspirin use, number and type of grafts, and
CPB times.
There were 4 deaths within 7 days of surgery (2.7%),
3 from cardiac events and 1 from ischemic bowel. Data
from these patients are included in the biochemical
analysis. Thirteen patients (9%) had biochemical evi-
dence of perioperative myocardial infarction, of whom
3 died. There was no significant difference among the
groups with respect to perioperative myocardial infarc-
tion or death.
Two patients had an elevated preoperative cTnT
(>0.2 µg/L), 1 of whom had a perioperative myocardial
infarction and the other an uneventful outcome.
The mean postoperative ventilation time and time to
discharge were not significantly different in the 3
groups.
Biochemical pattern of myocardial injury.  CK-
MB and cTnT concentrations increased from pre-dose
to peak values between 6 and 24 hours after CPB,
declining by 48 hours except in patients with perioper-
ative myocardial infarction, in whom peak values were
observed between 24 and 48 hours (Figs 1 and 2).
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Table I. Preoperative, intraoperative, and postoperative data on patients
PAF antagonist
Placebo 10 mg 100 mg Total P value
No. 50 50 50 150
Age (y) 62 (8) 63 (9) 62 (10) 62 (9) .9
Weight (kg) 82 (13) 85 (14) 83 (18) 83 (15) .7
Male sex (%) 84% 92% 86% 87% .5
Urgent operation (%) 25% 21% 29% 25% .6
Aspirin use (%) 26% 26% 29% 27% .9
Grafts 2.8 (0.6) 2.8 (0.6) 2.7 (0.6) 2.8 (0.6) .6
CPB time (min) 64 (18) 65 (15) 67 (22) 65 (18) .7
Cardioplegia (%) 2% 12% 16% 10% .06
Veins, LITA, BITA (%) 8, 48, 44 12, 62, 26 4, 64, 32 8, 58, 34 .2
Endarterectomy (%) 2% 6% 14% 7% .06
Myocardial infarction (%) 6% 6% 14% 9% .3
Ventilation (h) 3.5 (2.3) 4.3 (4.3) 5.3 (5.6) 4.4 (4.3) .17
Discharge (d) 6.3 (1.9) 6.8 (4.0) 6.8 (3.7) 6.6 (3.3) .7
Figures are presented as mean (SD) or percentage. P value is assessed by analysis of variance or Kruskal-Wallis, as appropriate. LITA, Left internal thoracic artery;
BITA, bilateral internal thoracic artery.
Stepwise multiple regression analysis showed that
duration of CPB was the strongest predictor of CK-MB
concentration at 1 (P < .002) and 6 hours (P < .02) and
of cTnT concentration at 1 (P < .001) and 6 hours (P <
.001) but at no other time point for either protein.
Effects of PAF antagonist. The mean (SD) area
under the curve for CK-MB in the 3 groups was as fol-
lows: placebo = 1004 (895), 10 mg lexipafant = 1148
(1275), and 100 mg lexipafant = 1564 (2134) (Fig 3).
When log transformed to account for skewed distribu-
tion, there was no significant difference among the 3
groups (P = .43, analysis of variance). The mean (SD)
area under the curve for cTnT in the 3 groups was as
follows: placebo = 45 (74), 10 mg lexipafant = 38 (39),
and 100 mg lexipafant = 62 (81) (Fig 4). When log
transformed to account for skewed distribution, there
was no significant difference among the 3 groups 
(P = .54, analysis of variance). By stepwise multiple
regression analysis, treatment group (ie, placebo, low-
dose, or high-dose lexipafant) did not significantly
influence CK-MB or cTnT at any time. 
Effects of bilateral ITA grafts. In this study 12
patients received vein grafts only, 87 received one
ITA and additional grafts, and 51 received bilateral
ITAs and additional grafts. The bilateral and single
ITA groups were similar with respect to number of
grafts (2.9 [0.4] vs 2.8 [0.7]) and CPB times (69 [12]
vs 65 [20] minutes). By stepwise multiple regression
analysis, the number of ITA grafts did not signifi-
cantly influence cTnT concentration at any time. In
contrast, the use of 2 ITA grafts accounted for a sig-
nificant (P = .02) elevation in CK-MB at 6 hours only
(Figs 5 and 6).
Effects of endarterectomy. Endarterectomy was
performed in 11 patients, of whom 1 died (9%). Six
(55%) of the patients undergoing endarterectomy had
biochemical evidence of a perioperative myocardial
infarct; 4 of these patients had at least minor changes in
the postoperative electrocardiogram, and 2 had an
unchanged electrocardiogram. Of the 13 biochemically
defined perioperative myocardial infarcts, 6 were asso-
ciated with endarterectomy and 7 were not in the
remaining 137 patients (Pearson χ2 P < .001). Stepwise
multiple regression analysis revealed that the perfor-
mance of endarterectomy resulted in highly significant
elevations of CK-MB at 6 hours (P = .01), 24 hours (P
< .001), and 48 hours (P < .001) and elevations in cTnT
at 24 (P < .001) and 48 hours (P < .001).
Myocardial protection. Fifteen patients received
antegrade cold crystalloid cardioplegia and 135 inter-
mittent crossclamp fibrillation. Stepwise multiple
regression analysis revealed that method of myocardial
protection did not have a significant influence on CK-
MB or cTnT elevation at any time. 
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Fig 1. CK-MB in patients with and without perioperative
myocardial infarction. The figure is presented as a box-plot
and whiskers. The central horizontal line represents the
median, and the bottom and top of the box represent the 25th
(lower quartile) and 75th (upper quarter) percentiles, respec-
tively. The whiskers represent smaller and larger values
which are not outliers.
Fig 2. cTnT in patients with and without perioperative
myocardial infarction. For explanation of format, see Fig 1.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 120, Number 4
Taggart 655
Fig 3.  CK-MB according to placebo, low-dose, or high-dose PAF antagonist (lexipafant). For explanation of for-
mat, see Fig 1.
Fig 4. cTnT according to placebo, low-dose, or high-dose PAF antagonist (lexipafant). For explanation of format,
see Fig 1.
Discussion
Detection of perioperative myocardial injury is impor-
tant for optimizing postoperative management, assessing
efficacy of myocardial protective strategies, and auditing
clinical outcome. Furthermore, perioperative myocardial
infarction may adversely affect long-term prognosis in
terms of subsequent ischemic events.21
Assesssment of myocardial injury. The prevalence
of myocardial injury depends on the method of detec-
tion. Functional assessment of contractile status is
dependent on loading conditions and cannot reliably
distinguish between stunning and irreversible injury.
Persistent new Q waves and more than 20% loss of R
waves provide reliable electrocardiographic evidence
of myocardial infarction but underestimate the inci-
dence of less severe degrees of myocardial injury. ST-T
wave changes are nonspecific, and conduction defects
can invalidate interpretation of postoperative electro-
cardiographic changes.
The conventional limitation of biochemical markers of
myocardial injury has been lack of specificity. Currently,
the most commonly used marker is CK-MB. However,
CK-MB is also released from skeletal muscle, albeit in
much lesser quantities than from cardiac muscle.
Troponins T, I, and C are part of the tropomyosin com-
plex that regulates muscle contraction and exists in car-
diac and skeletal muscle.6 The cardiac isoforms T and I
(cTnT, cTnI) have specific protein structures distinct
from the skeletal muscle variety. My colleagues and I1-4
have previously reported the value of these markers in
quantifying myocardial injury and the effects of various
interventions on the release of CK-MB and cTnT in
adults and children after cardiac surgery.
Pattern of biochemical response. The pattern of bio-
chemical response in this study is similar to that previ-
ously reported by us1-4 and others.5-9 Even in patients
without perioperative myocardial infarction, there were
still significant rises in CK-MB and cTnT levels at 6
hours before a decline toward baseline levels by 48
hours. The strongest predictor of elevations in CK-MB
and cTnT at 1 and 6 hours after surgery was the duration
of CPB. The functional significance of this early peak in
biochemical markers is uncertain but is unlikely to rep-
resent truly irreversible myocardial injury. Instead, it is
probably due to release of protein from non-structurally
bound cytosolic pools, which account for up to 6% of the
total cTnT in the cardiomyocyte.22 In the event of true
myocardial necrosis, cTnT levels would not peak for at
least 12 to 24 hours after the onset of necrosis and would
remain elevated for at least 5 days as the contractile
apparatus disintegrates.23
Prevalence of perioperative myocardial infarc-
tion. As discussed earlier, the lowest incidence of peri-
operative myocardial infarction is usually in studies
based on electrocardiographic changes, with a higher
incidence in studies based on biochemical criteria. In
this study and defined by a continuing rise in CK-MB
and cTnT above the level seen at 6 hours, 13 patients
(9%) had biochemical evidence of perioperative
myocardial infarction. Although this definition of
656 Taggart The Journal of Thoracic and
Cardiovascular Surgery
October 2000
Fig 5. CK-MB according to number of ITA grafts. For explanation of format, see Fig 1.
myocardial infarction may underestimate the incidence
of smaller focal areas of myocardial necrosis, it is con-
sistent with the expected pattern of protein release in
the event of true myocardial infarction. Furthermore,
this incidence of biochemically defined myocardial
infarction is in keeping with other current reports of
infarction in the range of 5% to 21% depending on the
technique of detection.5-10
Effects of PAF antagonist.  The rationale for the
use of a PAF antagonist to reduce myocardial injury is
based on its ability to reduce general activation and
“stickiness” of white blood cells16,17 and specifically
their role in ischemia-reperfusion injury.11,12,16-20 PAF
antagonists have been reported to reduce myocardial
injury in experimental ischemia-reperfusion injury in
terms of improved contractile status, reduced coro-
nary vasoconstriction, and arrhythmia,18-20 but to date
there has been no confirmatory evidence in the clini-
cal setting.
The higher dose of PAF antagonist administered in
this study produces serum levels equivalent to those
that have beneficial effects in acute pancreatitis.
Nevertheless, in the current study PAF antagonist in
low and high doses did not result in a reduction in bio-
chemical evidence of myocardial injury as judged at
individual times or by an integrated area under the
curve.
Effects of bilateral ITA grafts. Although excellent
clinical results are achievable with bilateral ITA grafts,
a slightly higher incidence of perioperative myocardial
infarction has been reported.24 Galbut and colleagues24
reported the incidence of perioperative myocardial
infarction at 2.1% in patients receiving bilateral ITA
grafts and 1.4% in patients receiving a single ITA graft.
In the current study, there was no difference in myocar-
dial injury in the use of bilateral ITA and single ITA as
defined by cTnT levels. Of particular note, however,
CK-MB was higher in the bilateral ITA group at 6
hours after CPB, almost certainly reflecting the addi-
tional injury to chest wall muscle as a consequence of
harvesting both ITA conduits and supporting the
increased cardiac specificity of cTnT.
Effects of endarterectomy. Although endarterecto-
my significantly increases the incidence of periopera-
tive myocardial infarction detected by electrocardiog-
raphy,25-27 there are no prospective studies examining
its effect on biochemical markers of myocardial
injury and in particular cTnT. In this study, 11 patients
underwent endarterectomy, of whom 6 (55%) had bio-
chemical evidence of myocardial infarction and of
whom 1 (9%) died. In the 6 patients with biochemical
evidence of infarction, the postoperative electrocar-
diogram was abnormal in 4 and normal in the remain-
ing 2, suggesting a higher incidence of infarction
when defined by biochemical markers. Of the 13
patients with definite perioperative myocardial infarc-
tion, 6 had endarterectomy (46%) in comparison to 7
of 137 patients (5%) without.
Cardioplegia. Only 15 patients had an operation per-
formed with cardioplegia rather than intermittent cross-
clamping and fibrillation. Regression analysis showed
no difference in CK-MB or cTnT release between these
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Fig 6.  cTnT according to number of ITA grafts. For explanation of format, see Fig 1.
2 methods of myocardial protection, consistent with
what we2 and others have previously reported.27,28 It is,
however, possible that the additional 5 to 10 minutes
required to perform endarterectomy compromises the
safety of the intermittent crossclamp and fibrillation
technique. Furthermore, this current study is not able to
answer concerns that ITA grafts may not provide as
optimal a blood supply as vein grafts to an endarterec-
tomized vessel.
Summary 
This study confirms the usefulness of biochemical
markers to assess potentially therapeutic interventions
and suggests that cTnT is a more specific marker of
myocardial injury than CK-MB. PAF antagonists, in
low and high doses, did not reduce perioperative
myocardial injury in clinical practice. Bilateral and sin-
gle ITA grafting results in similar levels of myocardial
injury, whereas endarterectomy is frequently associated
with biochemical evidence of myocardial injury.
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